MaxCyte, TG Therapeutics sign strategic platform license to advance autoimmune cell therapeutics programs
Source: SeekingAlpha
2025-02-12 03:56:54 ET
More on MaxCyte
- MaxCyte acquires SeQure Dx
- MaxCyte estimates higher Q4 core revenue from last year
- Seeking Alpha’s Quant Rating on MaxCyte
- Historical earnings data for MaxCyte
- Financial information for MaxCyte
Read the full article on Seeking Alpha
For further details see:
MaxCyte, TG Therapeutics sign strategic platform license to advance autoimmune cell therapeutics programs
MaxCyte Inc.
NASDAQ: MXCT
MXCT Trading
-5.91% G/L:
$1.035 Last:
580,117 Volume:
$1.09 Open:
MXCT Latest News
May 12, 2026 04:05:00 pm
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 GuidanceMXCT Stock Data
$82,138,988
103,153,769
1.05%
195
N/A
Biotechnology & Life Sciences
Healthcare
US
Rockville
